A record of what Nuvama Analysis said publicly, with the source. Not advice.
“Upgraded Dr. Reddy's Laboratories to 'buy' with a target price of ₹1,553, implying a 15% potential upside. The brokerage believes proactive measures, including the launch of Semaglutide in Canada by January 2026 and Abatacept biosimilar in the US in FY27, will mitigate about 80% of the anticipated EBITDA impact from Revlimid's patent expiry in 2026, suggesting a favorable risk-reward balance.”
Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹1,553, as stated.
Window: 12 months, the time frame the call states ("January 2026").
Neither the target ₹1,553 was reached on a close by the end of the window. Miss.
The grader’s working: R4 TARGET_CALL: entered ₹1371.6 on 2025-01-09 (next trading session's close); neither target nor stop reached by window end 2026-01-31. Window 388 days — rule H1: the quote states "January 2026".